| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
MindWalk Holdings Corp.
$1.33
+0.01 (+0.77%)
Market Cap
62.14 M
EPS
-0.19
P/E Ratio
-
Value Trade
287.98 K
2.15 %
Week
-2.35 %
1 Month
-20 %
3 Month
2.15 %
6 Month
-78.49 %
5 Year
-61.53 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
41.30 K
52 Week Range
0.99 - 2.99
% held by Insiders
9.45 %
% held by Institutions
9.29 %
Enterprise Value
72.09 M
Total Shares
46.71 M
Short %
1.56 %
Float Shares
45.65 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MindWalk Holdings Corp.
281Total events
3Upcoming
51Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 2
TBD
T3IND Enabling Complete
Subscribe to view catalyst details
TBD
T1Partnership / License
Subscribe to view catalyst details
Event history 2
TBD
●Oral PresentationPresentation
Subscribe to view catalyst details
TBD
●Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HYFT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HYFT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HYFT▲ +0.8%today
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 on September 14, 2026
MindWalk Holdings Corp. has announced its plans to report financial results for the first quarter of fiscal year 2027 on September 14, 2026. The company will also host a conference call at 5:00 p.m. Eastern Time, which will include a management presentation and a question-and-answer session. This event aims to provide insights into the company's performance and future direction.
Read more →HYFT▲ +15.3%on this news
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
MindWalk Holdings Corp. presented its ReefIQ platform at the Advancing AI 2026 event, emphasizing the importance of biological context in AI drug discovery. The demonstration highlighted how ReefIQ reconnects fragmented data to enhance AI reasoning. This innovation positions MindWalk among key players in the rapidly evolving AI-drug-discovery landscape, which is gaining investor attention.
Read more →HYFT▲ +15.3%on this newsshared move
MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI
MindWalk Holdings Corp. has publicly demonstrated ReefIQ™, its AI drug discovery tool, at AMD's Advancing AI event in San Francisco. This marks the first time ReefIQ™ has been showcased, emphasizing its biological context layer for enhancing AI applications in drug discovery. The demonstration is part of a broader collaboration with AMD.
Read more →HYFT▼ -18.1%on this newsshared move
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
MindWalk Holdings Corp. reported a 46% increase in revenue for fiscal 2026, reaching C$15.6 million, alongside its first contracted recurring revenue. The company's net loss narrowed significantly, showcasing a shift from project-based work to a more sustainable software business model. The report indicates a positive trend in financial performance, although risks remain due to the company's history of losses and the preliminary nature of the results.
Read more →HYFT▼ -18.1%on this newsshared move
MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure
MindWalk Holdings Corp. reported a 46% increase in revenue for fiscal 2026, marking a successful transition to deploying its Bio-Native AI technology. The company also saw an expansion in gross margins and a significant reduction in net loss. Additionally, it divested a non-core business, further streamlining its operations.
Read more →HYFTAs AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
MindWalk Holdings Corp. (NASDAQ:HYFT) is preparing to report its Q4 and full-year 2026 results on July 22, 2026. The company recently joined the Russell 3000E Index, enhancing its institutional visibility. MindWalk focuses on AI-driven drug discovery, particularly in GLP-1 metabolic health and infectious diseases, and has shown significant revenue growth. However, it faces risks typical of small-cap biotech firms.
Read more →HYFTMindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026
MindWalk Holdings Corp. has announced it will report its financial results for the fourth quarter and full fiscal year 2026 on July 22, 2026. The company will host a conference call at 5:00 p.m. Eastern Time, which will include a management presentation and a question-and-answer session. A press release with the financial results will be issued prior to the call.
Read more →HYFTAs AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models
MindWalk Holdings Corp. has filed a European patent application for its high-dimensional biological data architecture, which underpins its HYFT® Technology. This move aims to secure a competitive edge as AI models become more interchangeable. The company emphasizes the importance of structured data in drug discovery, anticipating significant growth in the AI sector of the pharmaceutical industry.
Read more →HYFTMindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity
MindWalk Holdings Corp. has been officially added to the Russell 3000E Index, which is expected to expand its institutional investment opportunities. This inclusion highlights the company's growing recognition in the market. Investors may see increased interest in the stock as a result of this development.
Read more →HYFTAs AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
MindWalk Holdings Corp. has filed a foundational patent application for its HYFT® Technology, focusing on a multi-dimensional data architecture that enhances biological data representation. This strategic move aims to protect the proprietary data layer that underpins its commercial platforms, as the AI landscape shifts towards data-driven competitive advantages. The patent application is expected to bolster MindWalk's market position as it continues to serve life-sciences customers.
Read more →HYFTMindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery
MindWalk has filed a patent for a new high-dimensional biological data architecture aimed at enhancing AI drug discovery processes. This innovation is expected to improve the efficiency and effectiveness of drug development. The details of the technology and its potential applications in the biopharma sector remain to be fully disclosed.
Read more →HYFTLa PDG de MindWalk (NASDAQ : HYFT), Jennifer Bath, participera à la table ronde organisée par Jones AI Day sur l’avenir de la découverte de médicaments par l’IA, à laquelle partipera Absci (NASDAQ : ABSI), un important fournisseur de services d'IA...
Jennifer Bath, CEO of MindWalk (NASDAQ: HYFT), will participate in a roundtable organized by Jones AI Day. The event will focus on the future of drug discovery through AI and will also feature Absci (NASDAQ: ABSI), a significant AI service provider. Details about the event and its implications for the industry are not provided.
Read more →HYFTMindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
Dr. Jennifer Bath, CEO of MindWalk, is set to participate in a panel discussion on AI drug discovery during Jones AI Day. She will join representatives from Absci and a leading AI compute provider. The event aims to explore the future of AI in the pharmaceutical industry.
Read more →HYFTMindWalk Holdings Corp. (NASDAQ : HYFT) lance ReefIQ™, une couche de contexte biologique au service de la découverte de médicaments par l’IA
MindWalk Holdings Corp. has launched ReefIQ™, a biological context layer aimed at enhancing drug discovery through AI. This initiative is expected to support more efficient and effective pharmaceutical research. However, further details on the technology and its applications are not provided in the article.
Read more →HYFTMindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery
MindWalk Holdings Corp. has announced the launch of ReefIQ™, a new biological context layer designed to enhance AI drug discovery. This innovative tool aims to improve the efficiency and effectiveness of drug development processes. The announcement highlights the company's commitment to integrating advanced technology in biopharmaceutical research.
Read more →HYFT▲ +13.2%on this news
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction
MindWalk Holdings Corp. reported positive preclinical data supporting its HYFT® technology, which identified a pan-serotype dengue target before immunization. The study demonstrated that immunogens designed based on this prediction elicited antibodies that cross-react with all four dengue serotypes. This finding not only validates the computational approach but also has implications for future vaccine development and AI-driven drug discovery.
Read more →HYFT▲ +13.2%on this newsshared move
MindWalk's Preclinical Dengue Data Support a HYFT Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across
MindWalk Holdings Corp. (HYFT) announced that its preclinical dengue data validate predictions made by its HYFT platform. Immunogens developed based on a computationally identified pan-serotype target elicited cross-reactive antibodies against all four dengue serotypes. This experimental evidence supports the platform's ability to derive meaningful biological insights, which may impact future dengue vaccine designs. The implications extend beyond dengue, as the HYFT platform aims to establish a reusable biological intelligence framework for various infectious diseases.
Read more →HYFT▲ +13.2%on this newsshared move
Les données précliniques de MindWalk sur la dengue corroborent une prédiction computationnelle HYFT® : les immunogènes conçus à partir de la cible prédite ont induit la production d'anticorps à réaction croisée contre les antigènes...
MindWalk Holdings Corp. has released preclinical data on dengue that supports a computational prediction made by its HYFT® platform. The data shows that immunogens designed from the predicted target induced cross-reactive antibody production against all four dengue serotypes. This validation marks a significant step in demonstrating the platform's predictive capabilities and its potential for future vaccine development.
Read more →HYFTMindWalk Holdings déploie une plateforme de réponse aux pandémies via la technologie HYFT® alors que les épidémies d'Ebola et d'hantavirus révèlent les limites de la couverture spécifique à chaque souche
MindWalk Holdings has launched a pandemic response platform utilizing HYFT technology. This initiative comes in light of the recent Ebola and hantavirus outbreaks, highlighting the need for improved strain-specific coverage. The platform aims to address these challenges effectively.
Read more →HYFTMindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage
MindWalk Holdings has deployed its Pandemic Response Platform utilizing HYFT® technology. This initiative comes in response to recent outbreaks of Ebola and Hantavirus, which have exposed the limitations of existing strain-specific coverage. The company aims to enhance pandemic preparedness through this technology.
Read more →HYFTC'est la biologie qui s'est imposée en premier.
The article does not provide any meaningful information or context regarding the topic. It appears to be incomplete or lacking in detail, making it difficult to derive any insights or news from it.
Read more →HYFT▲ +5.9%on this news· ran to +29% by day 3shared move
The Biology Came First. Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same
MindWalk Holdings Corp. has announced the successful advancement of over 20 partner-owned drug programs into clinical trials, driven by its antibody discovery work. Currently, ten of these programs are in active trials across oncology, immunology, neurology, and infectious disease. The company highlights its proprietary capabilities in immunization strategy and candidate selection, alongside a robust biological intelligence infrastructure. MindWalk continues to leverage its significant past research output, accumulating over 400 peer-reviewed publications and patents to enhance its discovery processes.
Read more →HYFT▲ +5.9%on this news· ran to +29% by day 3shared move
The Biology Came First.
The article titled 'The Biology Came First' provides minimal information, primarily focusing on the concept of being powered and protected by privacy. It lacks specific details or context regarding the topic, making it difficult to derive any substantial insights.
Read more →HYFT▲ +10.8%on this news
SEDI INSIDER ACTIVITY REPORT Period: March 18-27, 2026 | Source: SEDI Issuer No. 5542 | All prices USD (NASDAQ) WEEK SUMMARY Total Shares Acquired +66,500 common shares (open market) Total Capital Deployed USD $77,024 Av
The SEDI insider activity report for the period of March 18-27, 2026, highlights a total acquisition of 66,500 common shares in HYFT by insiders. A capital amount of USD $77,024 was deployed at an average price of $1.1583 per share. Notably, Tom Lynch and Scott Areglado increased their direct holdings, showcasing confidence in the company's outlook. Additionally, both executives received substantial Restricted Stock Unit grants, aligning their interests with shareholder value.
Read more →HYFTSEDI INSIDER ACTIVITY REPORT Period: March 16–20, 2026 | Source: SEDI Issuer No. 5542 | All prices USD (NASDAQ) WEEK SUMMARY Total Shares Acquired +60,000 common shares (open market) Total Capital Deployed USD $73
During the period of March 16 to 20, 2026, insider transactions reported significant activity with a total acquisition of 60,000 common shares in Charmquark by executives Dirk M.H. Van Hyfte and Ingrid M.H. Brands. The total capital deployed amounted to approximately $73,238, with an average purchase price of $1.2178 per share. This suggests that these insiders are optimistic about the stock’s future performance. No other transactions were recorded during this week.
Read more →HYFTThe following Management's Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of MindWalk Holdings Corp. (the Companyȁ
MindWalk Holdings Corp. has issued a Management Discussion and Analysis (MD&A) for the three and nine months ending January 31, 2026. The report details the company's focus on a software-led strategy, particularly with its LensAI platform, while discussing expectations for revenue growth and market trends in AI-driven drug discovery. The MD&A also highlights various risks and uncertainties that could impact the company's performance, such as challenges in adoption rates and regulatory compliance. Additionally, MindWalk has an emphasis on research and development across several therapeutic areas despite potential setbacks.
Read more →HYFTMindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI Platform Contract | Launch of B cell Llama Nanobody Discovery P
MindWalk Holdings Corp. reported financial results for Q3 Fiscal 2026, showcasing a 52% increase in revenue to $4.2 million, marking its third consecutive quarter of growth. The company has signed its first annual contract for its LensAI platform, shifting part of its revenue from project-based to recurring sources. Additionally, a new nanobody discovery platform, the B cell Llama, was launched aimed at overcoming historical limitations in antibody development. However, the company continues to face a net loss, albeit significantly reduced compared to the previous year.
Read more →HYFT▼ -5.1%on this news
MindWalk Announces B Cell Llama , a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic ac
MindWalk Holdings Corp. has unveiled B Cell Llama, a new platform focusing on the discovery of VHH nanobodies, which are positioned as essential for bispecific and CAR-T cell therapies. A recent peer-reviewed study validates the platform's potential, showing significant improvements in potency and the capability to overcome resistance. The B Cell Llama platform integrates AI to enhance the drug discovery process and aims to capitalize on the growing bispecific antibody market. However, its success is contingent on future clinical outcomes and market conditions.
Read more →HYFTMindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026
MindWalk Holdings Corp. will report its financial results for Q3 FY 2026 on March 12, 2026. A conference call will follow at 10:30 AM ET, featuring a management presentation and a Q&A session. The event will be accessible via a live webcast, allowing for broader participation from investors.
Read more →HYFTMindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics
MindWalk Holdings Corp. has announced the application of its HYFT technology to identify functional adjacency in drug discovery, which can lead to competitive and legal risks. The technology has demonstrated the ability to find shared biological signatures in influenza, suggesting potential for broader vaccine efficacy. This approach aims to enhance strategic decision-making in pharmaceutical R&D by focusing on functional similarities rather than just sequence alignment.
Read more →HYFT▼ -6.5%on this news
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
MindWalk Holdings Corp. has announced the discovery of monoclonal antibodies that target misfolded TDP-43, a protein linked to neurodegenerative diseases. This breakthrough validates their platform's ability to differentiate between toxic and healthy protein forms. The findings, while promising, are preliminary and subject to further validation.
Read more →HYFTMindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight Validated Across Influenza A and Influenza B, Including H3N2 Subclade K and Zoonotic Influenza A Subtypes H5, H7, H9 AUSTIN, Texas 
MindWalk Holdings Corp. has announced a significant advancement in its universal influenza program, identifying a functional constraint that persists across various influenza A and B strains using their proprietary HYFT Deep Data technology. This insight underscores the stable biological requirements for influenza infection, which may provide a foundation for more effective vaccine designs. However, uncertainties persist regarding the application of these findings in real-world vaccine development and the challenges posed by viral evolution.
Read more →HYFTMindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline VICTORIA, British Columbia –
MindWalk (NASDAQ: HYFT) reported significant financial growth for the second quarter of fiscal 2026, achieving a 54% increase in revenue and nearly doubling its gross profit to $2.7 million. The company is making strides in its AI-driven asset pipeline, with advancements in its GLP1 receptor agonist program and research toward a universal dengue vaccine. Additionally, MindWalk announced strategic rebranding and leadership expansions designed to enhance its operational focus and effectiveness. Upcoming updates are anticipated during the J.P. Morgan Healthcare Conference in January 2026.
Read more →HYFTMindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on
MindWalk Holdings Corp. has announced it will report its financial results and recent business highlights for the second quarter of fiscal year 2026 on December 15, 2025. The company will host a conference call at 10:30 AM ET to discuss these results. The call will include a question-and-answer session for participants. MindWalk, known for its Bio-Native AI therapeutic research, aims to leverage its patented technology in drug discovery and development.
Read more →HYFT▼ -7.8%on this news
MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025 AUSTIN, Texas--(BUSINESS WIRE) - MindWalk Holdings Corp. (“MindWalk,” “Company,” “we
MindWalk Holdings Corp. announces that its CTO, Dr. Dirk Van Hyfte, will participate in a fireside chat at the upcoming AI Drug Discovery & Development Summit 2025. The event, scheduled for November 20, 2025, aims to explore how artificial intelligence is revolutionizing drug discovery processes. Dr. Van Hyfte will share insights on MindWalk's HYFT-powered LensAi platform, which integrates biological knowledge to improve therapeutic development. The summit represents a key opportunity for MindWalk to present its innovative approaches in the bio-pharma industry.
Read more →HYFT▼ -6.1%on this news
MindWalk Holdings Corp. (the “Company” ) REVISED STATEMENT OF EXECUTIVE COMPENSATION for the fiscal year ended
MindWalk Holdings Corp. presented a revised statement of executive compensation for the fiscal year ended April 30, 2025. This statement details the roles of named executive officers (NEOs) and outlines the company's compensation philosophy, which aims to attract and retain senior executives while aligning pay with long-term success. The compensation program includes base salaries, short-term cash incentives based on corporate performance, and stock options. The Compensation, Nomination and Governance Committee also engaged a consulting firm to benchmark executive compensation against peer companies.
Read more →HYFTMindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy AUSTIN, Texas - MindWalk Holdings Corp. (“MindWalk,” “Company,” &#
MindWalk Holdings Corp. has appointed R. Scott Areglado as the new Chief Financial Officer, effective October 20, 2025, to enhance its financial strategy and growth. With over 25 years of experience in financial leadership within the healthcare and technology sectors, Areglado's expertise is expected to support MindWalk's Bio-Native AI platform as it scales globally. Additionally, the company held its 2025 Annual General Meeting where Dr. Jennifer Bath, Jon Lieber, and Dirk Witters were re-elected to the Board of Directors, while Kamil Isaev resigned after receiving only 32% of shareholder votes in favor for re-election.
Read more →HYFT▼ -5%on this newsshared move
MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion AUSTIN, Texas - MindWalk Holdings Corp. (“MindWalk,” “Company,” “we” or “
MindWalk Holdings Corp. has appointed Dr. Thomas W. Lynch as Chief Business Officer, effective October 20, 2025, to support the company's commercial expansion. Dr. Lynch brings over two decades of experience in biotechnology and software commercialization, previously holding leadership roles at Aldevron and DNASTAR. His expertise is expected to be instrumental for MindWalk as it expands its HYFT-powered Deep Data platform across global pharma and biotech markets. The company's focus is on capturing a share of the life sciences data analytics market, leveraging its Bio-Native AI technology.
Read more →HYFT▼ -5.3%on this news· ran to -17% by day 3shared move
Unaudited Pro Forma Financial Information Overview On
On August 6, 2025, MindWalk Holdings Corp. (NASDAQ: HYFT) announced the divestiture of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V., to AVS Bio for $12 million USD. The company provided unaudited pro forma financial statements adjusted for the divestiture, highlighting the potential impacts on its financial position. Despite the transaction, the company continues to face significant financial losses, and the divestiture does not meet the criteria for discontinued operations under IFRS guidelines. Investors are encouraged to review the unaudited financial information as a consideration for future performance.
Read more →HYFT▲ +5.3%on this newsshared move
Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligati
MindWalk Holdings Corp. conducted its annual general meeting on October 9, 2025, where voting results were disclosed. A total of four directors were nominated, with Kamil Isaev receiving insufficient votes to remain, leading to his resignation. The shareholders also approved the appointment of Davidson & Company LLP as auditors, demonstrating strong support for the board’s decisions. The results exemplify active shareholder participation in corporate governance.
Read more →HYFT▲ +5.3%on this newsshared move
MindWalk Announces Share Repurchase Program AUSTIN, Texas – MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company , today announc
MindWalk Holdings Corp. has announced a share repurchase program authorizing the repurchase of up to 2.3 million common shares, representing approximately 5% of its total outstanding shares. This initiative is aimed at demonstrating confidence in the company's growth prospects and optimizing capital allocation. The repurchase will be conducted based on market conditions and is intended to benefit shareholders, though it is not obligatory for the company to repurchase a specified amount of shares. The company plans to finance this program through existing funds and future cash flows.
Read more →HYFT▲ +16.2%on this news
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity Company builds on earlier GLP-1 success with breakthrough AI-led insights into aging biology -- targeting the w
MindWalk Holdings Corp. announced a significant development in its AI-designed GLP-1 therapeutics program, showcasing a first-in-class dual-pathway regimen aimed at enhancing healthspan and resilience in aging. Utilizing its LensAI platform, the company has identified a complementary pathway to GLP-1 biology, supporting the co-administration of its proprietary companion therapeutic. This strategic innovation builds on prior GLP-1 success and positions MindWalk to capitalize on the growing longevity therapeutics market, projected to exceed $60 billion by 2030. The company plans to advance its dual-pathway approach through preclinical evaluations and updates in the upcoming quarters.
Read more →HYFT▼ -20.4%on this news
MindWalk Holdings Corp.TM (formerly ImmunoPrecise AntibodiesTM) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet Company to hold conference call
MindWalk Holdings Corp. reported impressive financial results for the first quarter of fiscal 2026, with record revenues of $7.6 million, reflecting a year-over-year growth of 45%. The company also saw improvements in gross margins rising to 53% and a notable reduction in net losses. Strategic moves, including the divestiture of Netherlands operations that generated $16.1 million, have boosted their balance sheet and focused efforts on high-growth AI-driven initiatives.
Read more →HYFTMindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on
MindWalk (NASDAQ: HYFT) announced that it will host a conference call to discuss its financial results and business highlights for the first quarter of the fiscal year 2026 on September 15, 2025, at 10:30 am Eastern Time. The financial results will be shared in a press release prior to the call, which will also include a question-and-answer session. This event underscores the ongoing developments within the company as it operates in the TechBio and drug discovery sectors.
Read more →HYFTImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT” An Evolution in Name, Structure, and Strategy Reflecting the Company's AI-Driven Platform and Bio-Native Discovery Vision AUSTIN,
ImmunoPrecise Antibodies Ltd. has announced a corporate rebranding as MindWalk and a change of its NASDAQ ticker to HYFT. This change marks a strategic evolution towards an AI-driven platform that aims to unify multi-omics data and advanced research for drug discovery. The company is shifting from standalone wet-lab services to a scalable platform model, allowing for enhanced collaboration and intelligence-driven offerings in biologics research. However, the transition comes with potential risks related to operational execution and technology integration.
Read more →HYFTImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York AUSTIN, Texas, September 2nd, 2025 – ImmunoPrecise Antibodies Ltd. (the “Company” or
ImmunoPrecise Antibodies Ltd. announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference scheduled for September 8-10, 2025. Dr. Jennifer Bath, the company's President and CEO, will deliver a presentation and be available for one-on-one meetings with investors. This event represents a significant chance for the company to showcase its advancements and engage directly with stakeholders.
Read more →HYFTImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation Manufacturing of validated dengue epitope underway; proprietary immunization studies in r
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced significant progress in its universal dengue vaccine initiative, transitioning to preclinical antibody generation. The company is utilizing its proprietary HYFT technology to produce a validated dengue epitope for testing in rabbit models. These studies aim to evaluate the vaccine's effectiveness in eliciting monoclonal antibody responses. This marks a crucial step in translating AI-based discoveries into real-world applications for infectious disease vaccines.
Read more →HYFTImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation AUSTIN, TEXAS  – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the ȁ
ImmunoPrecise Antibodies Ltd. has successfully divested its Netherlands subsidiary to AVS Bio for a total enterprise value of $12 million USD. This strategic decision allows ImmunoPrecise to streamline operations and concentrate on its AI-based initiatives, including the LENSai platform. The transaction generated significant net proceeds that will be reinvested into data-driven technologies aimed at advancing drug discovery. A 12-month Transition Services Agreement will ensure continuity during the transition period, though there are no ongoing relationships with AVS Bio beyond this sale.
Read more →HYFTImmunoPrecise Antibodies Ltd. 3204-4464 Markham Street Victoria, BC, Canada V8Z 7X8 PH: +1 (250) 483-0308 Website: www.ipatherapeutics.com Email: info@ipatherapeutics.com Date
ImmunoPrecise Antibodies Ltd. announced its upcoming Annual General Meeting, scheduled for October 9, 2025. The record date for notice and voting is set for August 27, 2025. The meeting will be held virtually, and materials related to the meeting will not be sent directly to Non-Registered Owners. This announcement serves as a formal communication to all relevant securities regulatory authorities and stakeholders.
Read more →HYFTImmunoPrecise Antibodies (IPA) Reports Record Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted
ImmunoPrecise Antibodies Ltd. reported record financial results for Fiscal Year 2025, with total revenues of $24.5 million and notable growth in its BioStrand segment. The company's fourth quarter also saw its highest revenue to date, reflecting significant operational improvements and strategic advancements in AI-driven drug discovery. Despite a net loss of $30.2 million, the financial performance indicates a path toward profitability and enhanced investor confidence. Future plans include a focus on AI-based product development using the LENSai platform, underscoring the company's commitment to innovation.
Read more →HYFTImmunoPrecise Releases New Findings Showing LENS ai Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic AUSTIN, Texas   - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the &#x
ImmunoPrecise Antibodies Ltd. has announced new findings regarding its LENSai Immunogenicity Screening platform, which can effectively predict the risk of Anti-Drug-Antibody (ADA) before therapeutic proteins enter clinical trials. The study indicates that LENSai significantly reduces the time and costs associated with identifying high-risk candidates by utilizing an advanced, alignment-free screening process that evaluates a wide range of HLA variants. This innovation aims to mitigate the 40% failure rate linked to ADA during late-stage development, potentially improving outcomes for drug developers.
Read more →HYFTImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board AUSTIN, Texas   - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI com
ImmunoPrecise Antibodies Ltd. has appointed Jeff Fried, a leader in healthcare data and AI innovation, to its Advisory Board. Fried brings over 25 years of experience and is expected to enhance the company's LENSai platform, which aims to improve data interoperability in life sciences. His advocacy for this platform underscores ImmunoPrecise's commitment to revolutionizing drug discovery and diagnostics with bio-native AI technologies. The appointment reflects a strategic move to advance the integration of data-driven solutions in healthcare.
Read more →HYFTImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement AUSTIN, Texas  – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a company operat
ImmunoPrecise Antibodies Ltd. has announced its compliance with Nasdaq's minimum bid price requirement, confirming that its share price has been above $1.00 for ten consecutive business days. This achievement reflects the company's evolution into a platform based on bio-native AI, as stated by CEO Dr. Jennifer Bath. The LENSai platform, leveraging HYFT technology, enables rapid and precise therapeutic discovery through advanced data integration, positioning ImmunoPrecise at the forefront of innovation in the biotech sector.
Read more →HYFTImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors AUSTIN, Texas  – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-p
ImmunoPrecise Antibodies Ltd. has appointed Jon Lieber to its Board of Directors, effective immediately. Lieber, who has over 30 years of experience in finance and corporate leadership within biotechnology, is expected to contribute significantly to the company's growth and strategic direction. He previously served as CFO at Rallybio and has experience in Nasdaq governance. Dr. Jennifer Bath, CEO of ImmunoPrecise, expressed optimism about Lieber's role during this transformative period for the company, which aims to enhance its AI-powered drug discovery capabilities.
Read more →HYFTImmunoPrecise Validates LENS ai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data New benchmark confirms LENS ai 's ability to accurately predict binding on 17 previously unse
ImmunoPrecise Antibodies Ltd. announced a successful validation of its LENSai Epitope Mapping platform, demonstrating its ability to accurately predict antibody binding sites on 17 unseen antibody-antigen complexes. This breakthrough shows that LENSai can generalize predictions to new targets without the need for extensive training data, aligning with wet-lab results. The findings highlight significant advancements in accelerating therapeutic discovery while reducing timelines and costs. The company is positioned to expand partnerships with its validated AI technology, streamlining drug development processes.
Read more →HYFTAI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies Breakthrough in AI-powered drug discovery validates HYFT -driven peptide design, with broad potential across mul
ImmunoPrecise Antibodies has reported that its AI-designed GLP-1 receptor agonist peptides demonstrate receptor activation comparable to that of Semaglutide. The findings validate the company's HYFT technology and highlight its potential for rapid development in various therapeutic areas. With promising preclinical paths in both injectable and non-invasive delivery strategies, ImmunoPrecise seeks to leverage this technology further for subsequent drug development, following previous successes in vaccine development. This advancement signifies a potential shift in drug discovery methodologies toward the use of AI.
Read more →HYFTImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENS ai platform powered by patented HYFT Technology Follow-Up to
ImmunoPrecise has made significant progress in developing a universal dengue vaccine, confirming its candidate's safety, immune activation, and structural stability using its LENSai platform. The newly validated vaccine target shows promise, being conserved across all four dengue virus types and activating key immune responses. The company is moving forward in the vaccine development process, showcasing the capabilities of its patented HYFT technology for rapid and validated drug discovery. This development comes at a crucial time as there is a growing demand for effective and safer dengue vaccines.
Read more →HYFTImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery LENS ai powered by HYFT technology Identifies a single multi-factorial target conserved across all dengue serotypes. AUSTIN, Texas - Im
ImmunoPrecise Antibodies has announced a significant breakthrough using its LENSai platform powered by HYFT technology, having identified a conserved epitope across all dengue virus serotypes. This discovery could lead to the development of a universal dengue vaccine, addressing challenges faced by traditional vaccine research. Additionally, the company plans to expand its AI-driven vaccine design approach to other infectious diseases like HIV and Norovirus. The findings may also have implications for oncology applications, indicating the potential of AI-driven solutions in biotherapeutic developments.
Read more →HYFTImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
ImmunoPrecise Antibodies Ltd. has announced its collaboration with CORE IR, a strategic investor and public relations firm. This partnership aims to enhance investor awareness and shareholder engagement while improving communication with the investment community. The CEO of ImmunoPrecise, Dr. Jennifer Bath, expressed optimism that CORE IR's expertise will aid in articulating the company’s value to current and prospective shareholders. The engagement will involve a range of investor relations services, including strategic messaging and outreach.
Read more →HYFTIPA's LENS ai Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driv
ImmunoPrecise Antibodies Ltd. (IPA) announced significant advancements in its LENSai platform, which now matches the accuracy of gold-standard epitope mapping methods, such as x-ray crystallography, while dramatically reducing the time required for analysis. This AI-driven technology provides rapid and scalable insights for antibody discovery, addressing common industry challenges like high failure rates and lengthy lab processes. The achievements were confirmed through a benchmarking study, marking a pivotal moment for IPA's innovations in computational biology. The development aligns with increasing regulatory support for new methodologies in biotherapeutics.
Read more →HYFTImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai with FDA's Shift to Non-Animal Testing Methods AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-drive
ImmunoPrecise Antibodies Ltd. announced its support for the FDA's move to phase out animal testing for monoclonal antibodies and other pharmaceuticals. The company's proprietary AI platform, LENSai, is designed to aid this shift by providing advanced methodologies that align with New Approach Methodologies (NAMs). The CEO, Dr. Jennifer Bath, emphasized the inadequacy of traditional animal models for predicting human biology and the importance of ethical, efficient drug development processes. This policy change may help improve drug safety, efficacy, and streamline preclinical workflows.
Read more →HYFTIPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy AUSTIN, Texas--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. has announced a strategic collaboration with RIBOPRO to advance mRNA-driven antibody discovery aimed at enhancing immunotherapy. The partnership will integrate RIBOPRO's mRNA technology with IPA's antibody discovery capabilities, focusing on improving antigen expression and immune responses. This collaboration is set to accelerate the development of novel therapeutics by overcoming traditional challenges in antibody discovery methods. Overall, the initiative represents a significant step forward in the integration of artificial intelligence and innovative biotechnologies in drug development.
Read more →HYFTImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Lead
ImmunoPrecise Antibodies (IPA) has reported its financial results for the third quarter of its fiscal year 2025, highlighting a strategic partnership worth $8-$10 million to bolster its drug discovery capabilities. The company also announced expansions in its AI infrastructure and notable leadership appointments aimed at enhancing its growth trajectory. Despite securing high gross margins and showcasing resilience in challenging market conditions, IPA faced significant increases in net loss and impairment charges, which could raise concerns among investors. Overall, the company remains committed to its innovative AI-driven initiatives and strategic investments for future growth.
Read more →HYFTThe following Management's Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (“the
ImmunoPrecise Antibodies Ltd. released its Management's Discussion and Analysis for the three and nine months ending January 31, 2025. The company's performance was reviewed and approved by its Board of Directors on March 27, 2025. It emphasizes its growth in revenues, strategic expansions, and innovative technology development, including its proprietary HYFT technology and integrations of in silico methodologies with wet lab operations. The MD&A also outlines caution regarding forward-looking statements and non-IFRS measures used in assessing the company’s results.
Read more →HYFTImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. Programs to be Driven Through Patented AI Technology and Advanced Proprie
ImmunoPrecise Antibodies Ltd. has entered a strategic partnership with a major biotechnology company focused on developing cancer therapeutics. The collaboration, valued at $8M-$10M, will utilize AI technology and proprietary platforms to advance the discovery and optimization of Antibody-Drug Conjugates and bispecific antibodies. This initiative aims to enhance efficiencies in therapeutic development over an 18 to 24-month period. The partnership highlights the potential of combining advanced technology with antibody engineering to address unmet medical needs in cancer treatment.
Read more →HYFTIPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on
ImmunoPrecise Antibodies Ltd. has announced the rescheduling of its Third Quarter Fiscal 2025 financial results to March 28, 2025. Originally set for March 13, the delay is intended to give auditors more time to complete their reviews related to goodwill and intangible asset valuations. The company will also host an earnings call on the same day at 10:30 AM Eastern Time to discuss the financial results and provide a corporate update.
Read more →HYFTImmunoPrecise Antibodies Announces Key Leadership Changes AUSTIN, TEXAS, – ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and tech
ImmunoPrecise Antibodies has announced significant leadership changes, including the appointment of Kamil Isaev to the Board of Directors and Joseph Scheffler as Interim Chief Financial Officer. Isaev brings extensive experience in AI and technology commercialization, while Scheffler has over 20 years of financial management experience. The company also mentioned the departure of Chris Buyse from the Board, acknowledging his contributions during a transitional phase. These changes are expected to support the continued growth of IPA's AI-driven biologics initiatives.
Read more →HYFTImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture IPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position fo
ImmunoPrecise Antibodies Ltd. announced the successful completion of an $8.8 million at-the-market equity offering and the full conversion of its outstanding debenture with Yorkville Advisors. This strategic capital initiative has enhanced the company's financial position and eliminated near-term debt obligations. CEO Dr. Jennifer Bath emphasized that these moves reflect strong investor confidence and provide the company with the flexibility needed to pursue growth initiatives. With these changes, ImmunoPrecise is now well-positioned to advance its AI-driven therapeutic discovery platform, LENSai.
Read more →HYFTIPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment. AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GL
ImmunoPrecise Antibodies Ltd. (IPA) has unveiled a new class of GLP-1 therapies designed through its AI-driven LENSai platform, aiming to enhance efficacy and patient satisfaction in diabetes treatment. These therapies are being developed to potentially allow for non-invasive delivery methods and improved dosing regimens. The platform's rapid sequence generation indicates a significant evolution in drug discovery processes, although future results may be subject to regulatory and competitive uncertainties. IPA’s innovative approach seeks to redefine biologics and expand therapeutic capabilities.
Read more →HYFTImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its
ImmunoPrecise Antibodies Ltd. has launched an AI-driven pipeline aimed at transforming drug discovery via a first-principles approach. This new system integrates vast biological datasets with advanced artificial intelligence, promising improved efficiency and effectiveness in therapeutic development. The proprietary AI platform, LENSai, is intended to streamline processes and enhance the reliability of new therapies. Despite potential advancements, the company acknowledges inherent uncertainties tied to technological and regulatory challenges.
Read more →HYFTFiled by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company ImmunoPrecise Antibodies Ltd. (the Company ) 3204 4464 Markham Street, Victoria, British Columbia, V8Z 7X8, Canada Item 2
ImmunoPrecise Antibodies Ltd. announced the resignation of Kristin Taylor as Chief Financial Officer, effective January 16, 2025. Taylor will remain with the company in a consulting capacity after her resignation. The company is starting a succession process for her replacement and will provide updates as necessary. The announcement highlights both a significant change in leadership and the company's commitment to financial stability.
Read more →HYFTImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases VICTORIA, BRITISH COLUMBIA (CANADA)
ImmunoPrecise Antibodies Ltd. (IPA) announced substantial insider share purchases totaling 763,120 shares worth USD $306,000 by its CEO and co-founders. This insider activity signals confidence in the company's strategic direction and future growth. The leadership emphasizes their commitment to long-term shareholder value and advancing initiatives in AI-driven biotherapeutics. The company's integrated platform aims to address complex challenges in the life sciences sector.
Read more →HYFTImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 Delivers $6.1 Million Q2 Revenue and Announces Strategic Plan to Reshape Biotech and AI-Driven D
ImmunoPrecise Antibodies (IPA) announced its financial results for Q2 FY25, reporting revenues of $6.1 million, a 16% increase from the previous quarter. The company is embarking on a strategic plan that includes relocating its headquarters to Austin, Texas, to expand its footprint in the biotech and AI sectors. IPA showcased advancements in its LENSai platform and made notable progress in cancer research collaborations, despite experiencing a net loss of $2.6 million this quarter.
Read more →HYFTIPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on
ImmunoPrecise Antibodies Ltd. (IPA) has announced that it will host a conference call on December 10, 2024, to discuss its financial results for the second quarter of fiscal year 2025. The call will follow a press release detailing the financial information. Participants can join the live call or access a replay thereafter, with additional information available on the company's investor relations pages. This event signifies IPA's ongoing commitment to transparency and communication with its investors.
Read more →HYFTBillion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies Innovative Antibodies Show Promise for Antibody-Drug Conjugate (ADC) Development, Paving the Way for
ImmunoPrecise Antibodies Ltd. (IPA) has announced a breakthrough in the development of high-impact antibodies for next-generation antibody-drug conjugates (ADCs) targeting TrkB proteins, which are prevalent in aggressive cancers. The promising results from the TATX-112 program indicate that multiple antibodies can effectively target and eliminate TrkB-expressing cells, setting the stage for enhanced cancer treatments. This accomplishment places IPA strategically in the rapidly expanding market projected to reach over $20 billion by 2028. Dr. Jennifer Bath, CEO of IPA, expressed confidence in the company's innovative capabilities fueled by AI-driven processes.
Read more →HYFTImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation VICTORIA, BRITISH COLUMBIA (CANADA)
ImmunoPrecise Antibodies Ltd. announced its upcoming TECHDAY event for November 15, 2024, which will feature presentations and demonstrations on advancements in AI and biologics. Key presentations include Dr. Dirk Van Hyfte discussing the LENSai platform and Dr. Shuji Sato elaborating on the B Cell Discovery Platform. The event aims to highlight innovative strategies for enhancing drug discovery through technology integration. A recorded webcast will be available for stakeholders and interested parties after the event.
Read more →HYFTImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology Rabbit B Cell Select Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dys
ImmunoPrecise Antibodies Ltd. has announced its significant role in a study conducted by the Mayo Clinic, focusing on antibodies that detect mitochondrial damage related to aging. The study, published in the journal Autophagy, highlights advancements in understanding mitochondrial health and its implications for neurodegenerative diseases. The company's Rabbit B Cell Select platform facilitated the development of these novel antibodies, positioning ImmunoPrecise to capitalize on the growing anti-aging market forecasted to reach $81 billion by 2028. CEO Dr. Jennifer Bath emphasized the potential clinical applications of these findings.
Read more →HYFTImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 VICTORIA, BRITISH COLUMBIA (CANADA)
ImmunoPrecise Antibodies Ltd. announced its participation in the AI Driven Drug Discovery Summit USA 2024. Dr. Dirk Van Hyfte, Head of Innovation at IPA's AI subsidiary, will feature in a Fireside Chat at the event held in Boston from November 12-14, 2024. This participation highlights the company’s continued involvement in advancing AI technologies for therapeutic antibody development. With a focus on innovative solutions, IPA showcases its leadership role in the biopharmaceutical field.
Read more →HYFTFiled by newsfilecorp.com Date
The article announces the details of the Annual General Meeting for ImmunoPrecise Antibodies Ltd., scheduled for November 14, 2024. Key dates include the record date for notice and voting, which is set for October 15, 2024. The meeting will be held virtually, and information regarding proxies and access requirements is also outlined. Additional details about the securities involved are provided but do not indicate any significant changes or events affecting the company.
Read more →HYFTImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design University of Washington's Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biothera
ImmunoPrecise Antibodies celebrates the recent Nobel Prize in Chemistry, awarded to David Baker and the team at Google DeepMind for their work in computational protein design and protein structure prediction. This recognition highlights the importance of AI in understanding protein structures, aligning with ImmunoPrecise's initiatives. Their proprietary AI platform, LENSai, aims to revolutionize drug discovery by integrating advanced AI technologies. The company is also focused on expanding collaborations within academia and industry to explore further opportunities in developing novel therapies.
Read more →HYFTImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus Talem Therapeutics' Antibody Asset to be Evaluated for Bispecific Development Against Solid Tumors VICTORIA, BRITISH COLUMBIA (CANADA), ZHUHAI, (CH
ImmunoPrecise Antibodies Ltd. and Biotheus Inc. have entered into a Material Transfer and Evaluation Agreement for an antibody asset aimed at developing bispecific therapies for solid tumors. This collaboration intends to leverage ImmunoPrecise's AI-driven platform to create innovative cancer-fighting drugs that target hypoxic tumor environments. If successful, the evaluation may accelerate the progress of these therapies into clinical trials, potentially transforming treatment options for patients with cancer. Both companies expressed optimism about the future of their partnership and the advancements it could foster in oncology.
Read more →HYFTImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments Rabbit B Cell Select Drives Clinical Breakthroughs in Cancer Treatment VICTORIA, BRITISH COLUMBIA (CANADA)
ImmunoPrecise Antibodies Ltd. has announced significant advancements in rabbit monoclonal antibody development, particularly through its B Cell Select platform. Two promising candidates, OR502 and OR641, are progressing in clinical trials aimed at treating advanced solid tumors. OR502 has entered Phase I/II trials, while OR641 is undergoing IND-enabling studies. The company's innovations are recognized as a potential breakthrough in cancer therapies.
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. 3204 - 4464 Markham Street Victoria, British Columbia V8Z 7X8
ImmunoPrecise Antibodies Ltd. has filed its Statement of Executive Compensation for the financial year ending April 30, 2024. The report outlines compensation for its named executive officers, including salaries, short-term incentives, and stock options. The company aims to attract high-quality executives and provide compensation competitive with peer companies. Additionally, an analysis by Arnosti Consulting was conducted to ensure executive pay aligns with market standards.
Read more →HYFTThe following Management's Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. (the Company
ImmunoPrecise Antibodies Ltd. (IPA) has released its Management's Discussion and Analysis (MD&A) for the three months ended July 31, 2024. The document outlines the company's financial statements in compliance with IFRS and highlights forward-looking statements regarding its business strategies, particularly its focus on AI technologies and expansion in Europe. While there is optimism around revenue growth and innovation, there are also risks associated with market acceptance and regulatory factors that could influence future performance.
Read more →HYFTImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 Achieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End U
ImmunoPrecise Antibodies (IPA) reported its financial results for the first quarter of fiscal year 2025, achieving $5.3 million in revenue. Despite the positive revenue growth at two sites, the company incurred a net loss of $4.0 million, an increase from the previous year. IPA's strategic advancements with its LENSai platform have led to innovative antibody development, and cash reserves have decreased compared to the same period last year. The company remains focused on long-term growth and operational efficiency amid the competitive landscape.
Read more →HYFTImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York VICTORIA, BRITISH COLUMBIA (CANADA)
ImmunoPrecise Antibodies Ltd. has announced its participation in H.C. Wainwright's 26th Annual Global Investment Conference, scheduled to take place from September 9 to September 11, 2024, in New York. The company invites shareholders and potential investors to attend the conference, which will feature in-person and virtual options. This event allows ImmunoPrecise to engage with industry professionals while presenting its biotherapeutics capabilities. The company's management will also conduct one-on-one meetings to discuss their business and investment opportunities.
Read more →HYFTImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements VICTORIA, BRITISH COLUMBIA (CANADA)
ImmunoPrecise Antibodies Ltd. received a notification from Nasdaq indicating its common shares have been trading below the minimum bid price requirement of $1.00 for 30 consecutive business days. While this notification highlights a deficiency, it is not a notice of imminent delisting and currently has no immediate effect on the company's listing or trading. The company continues to operate and is focused on developing biotherapeutics using advanced AI technologies.
Read more →HYFTImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENS ai Technology Engineering antibodies in silico using LENS ai marks a significant milestone toward the
ImmunoPrecise Antibodies has successfully engineered antibodies for a challenging tumor microenvironment protein using its patented LENSai technology. This breakthrough is notable as it was achieved without any prior structural information about the target protein. The antibodies have been shown to have highly specific binding and do not affect healthy cells, potentially leading to safer cancer treatments. This development emphasizes the capabilities of LENSai in revolutionizing the field of antibody engineering and accelerating the drug discovery process.
Read more →HYFTImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 Achieves Record $24.5 Million Revenue in FY 2024, Showcases Technological Advancements Expands La
ImmunoPrecise Antibodies (IPA) reported significant financial results for the fiscal year 2024, achieving record revenues of $24.5 million, a 19% increase from the previous year. The company showcased technological advancements, particularly with the commercial launch of its LENSai API and enhancements to its AI technologies. However, IPA faced challenges with a net loss of $18 million in Q4, attributed largely to an impairment charge linked to BioStrand's assets. Despite these challenges, IPA's strategic investments in innovation and a robust market demand suggest a strong growth trajectory.
Read more →HYFTImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year End 2024 The Company to host an earnings conference call via webcast VICTORIA
ImmunoPrecise Antibodies Ltd. has rescheduled its full-year fiscal 2024 financial results to July 29, 2024, allowing auditors additional time for necessary reviews. The decision highlights the company's commitment to ensure accurate and compliant financial reporting. An earnings conference call will take place at 10:30 am Eastern Time on the same day, accessible through their Investor Relations website.
Read more →HYFTFiled by newsfilecorp.com ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
ImmunoPrecise Antibodies Ltd. has announced a financing agreement with Yorkville Advisors Global, LP for up to $3.0 million in convertible debentures. The transaction consists of two tranches, with an initial $2.0 million already completed and a subsequent $1.0 million expected upon SEC registration. The funds will be allocated for research and development, operational expenses, and capital expenditures. The terms include an 8% annual interest and specific conditions related to stock price performance, which may lead to mandatory repayments.
Read more →HYFTIPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 The Company to host an earnings conference call via webcast VICTORIA, BRITISH COLUMBIA (CANADA
ImmunoPrecise Antibodies Ltd. (IPA) plans to announce its financial results and business highlights for the fiscal year 2024 on July 25, 2024. The announcement will be followed by an earnings conference call at 10:30 AM Eastern Time. The company utilizes advanced technologies in biotherapeutic research and offers a comprehensive suite of services to support partners in discovering novel biologics. With various subsidiaries across North America and Europe, IPA is positioned to share insights into its operations and future strategies during the call.
Read more →HYFTImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer VICTORIA, BRITISH COLUMBIA (CANADA)
ImmunoPrecise Antibodies Ltd. has announced the permanent appointment of Kristin Taylor as Chief Financial Officer, effective immediately. Ms. Taylor, who has been serving as Interim CFO since September 2023, brings a wealth of experience from her previous roles in various financial leadership positions. Her expertise in driving growth and establishing effective strategies positions her well to lead the company's financial operations moving forward. The announcement reflects the company's confidence in her ability to enhance their strategic initiatives.
Read more →HYFTIPA's Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENS ai VICTORIA, BRITISH COLUMBIA (CANADA)
ImmunoPrecise Antibodies Ltd. (IPA) has announced a strategic collaboration between its subsidiary BioStrand and PGxAI to develop an innovative AI model for pharmacogenomic recommendations using the LENSai system. This partnership seeks to leverage advanced AI technology to better analyze genetic data and enhance personalized medicine, aiming to improve patient outcomes and predict drug responses. The collaboration highlights the growing importance of pharmacogenomics in medical practices and its potential to transform drug prescription and treatment efficiency, though it comes with inherent risks and uncertainties in actual implementation.
Read more →HYFTFiled by newsfilecorp.com ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENS ai Technology VICTORIA, British Columbia
ImmunoPrecise Antibodies Ltd.'s subsidiary, BioStrand, has been awarded the 2024 Impact Award at the InterSystems Global Summit for its innovative LENSai technology. This recognition highlights BioStrand's contributions to the field of biotherapeutics, emphasizing its role in advancing research and setting new standards in innovation. The award will be presented in a dedicated ceremony attended by industry leaders, reflecting the significant impact of BioStrand's work.
Read more →HYFTFiled by newsfilecorp.com BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery -BioStrand now offers
BioStrand, a subsidiary of ImmunoPrecise Antibodies, has announced the commercial release of its innovative LENSai API software designed for AI-driven drug discovery. This software allows integration of large databases and electronic health records, significantly enhancing the capabilities of pharmaceutical and healthcare companies. The launch will be highlighted during presentations at the InterSystems Global Summit 2024, where industry leaders are expected to explore the potential of this technology. The product aims to address ongoing challenges in drug development and facilitate better access to crucial data.
Read more →HYFTFiled by newsfilecorp.com IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR) Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at t
BioStrand, a subsidiary of IPA, has announced the application of its advanced Large Language Model, LENSai, to improve the analysis of Electronic Health Records for drug discovery. This tool aims to enhance the integration of real-world data, facilitating the development of precision medicines. Dirk Van Hyfte, IPA's Head of Technology, will present a live demonstration of the technology at the upcoming InterSystems Global Summit 2024. The company positions itself as a leader in leveraging EHRs to drive innovation in the biopharmaceutical industry.
Read more →HYFTFiled by newsfilecorp.com InterSystems and IPA's Subsidiary BioStrand Unveil the Innovative Integration of Vector Search with LENS ai for AI- Driven Healthcare Applications VICTORIA, BRITISH COLUMBIA (CANADA)
InterSystems and ImmunoPrecise Antibodies Ltd. have announced a collaboration to integrate InterSystems' Vector Search technology with BioStrand's LENSai platform. This innovative combination aims to enhance AI-driven applications within healthcare and life sciences, facilitating better data analysis and quicker drug discovery. The partnership reflects both companies' commitment to innovation in a rapidly growing AI market. Despite the promising outlook, the partnership carries inherent risks, particularly concerning the uncertain outcomes of the integration and its impact on healthcare benefits.
Read more →HYFTFiled by newsfilecorp.com IPA Acquires the Carterra LSA Instrument to Enhance Antibody Discovery and Bolster Its AI Developments Significant throughput of LSA to advance IPA's diversity- and data-driven drug development
ImmunoPrecise Antibodies Ltd. has announced the acquisition of the LSA instrument platform from Carterra, which will enhance its antibody discovery and AI-driven drug development capabilities. The LSA instrument allows for high throughput surface plasmon resonance-based antibody characterizations, significantly increasing IPA's capacity for various protein interaction analyses. This strategic move aims to improve efficiency in drug discovery, leveraging large data sets to optimize models in in silico drug development. However, the announcement includes forward-looking statements that indicate potential risks related to achieving their anticipated outcomes.
Read more →HYFTFiled by newsfilecorp.com IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* IPA reports a fourth consecutive quarter of increased revenue. VICTORIA, BRITISH COLUMBIA (CANADA
ImmunoPrecise Antibodies Ltd. (IPA) reported its financial results for the third quarter of FY2024, highlighting a fourth consecutive quarter of increased revenue. The company achieved record revenues of $6.2 million, reflecting a 20.3% increase compared to the same period last year. Additionally, IPA announced a significant decrease in cash burn, attributed to both increased revenue and strategic cost management. The results underscore the effectiveness of IPA's business strategy, including advancements in antibody discovery and development services.
Read more →HYFTFiled by newsfilecorp.com IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology Dirk Van Hyfte MD, PhD, Co-Founder and Head of
BioStrand, a subsidiary of IPA, has launched a Foundation AI Model that integrates advanced stacking of Large Language Models (LLMs) with patented HYFT technology. This new model significantly enhances the analysis of complex biological data, potentially transforming drug discovery and precision medicine. The AI model's capability to decode protein structures and functions leads to more accurate predictions in biotherapeutic development. BioStrand's findings will be presented at the HIMSS24 conference, highlighting their commitment to innovation in the life sciences sector.
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three and six months ended
ImmunoPrecise Antibodies Ltd. released its condensed interim consolidated financial statements for the periods ended. The information presented is heavily focused on financial categories without offering substantial insights into the company's strategic direction or performance metrics. As such, it does not provide investors with meaningful context to assess the company's current standing or prospects.
Read more →HYFTThe following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd. ("the Company", "ImmunoPre
ImmunoPrecise Antibodies Ltd. (IPA) has released its Management's Discussion and Analysis along with unaudited financial statements for the periods ended October 31, 2023. The MD&A outlines IPA's forward-looking information and the strategic integration of in silico technologies with wet lab capabilities in its operations. The company underscores its commitment to innovative solutions in biotherapeutic development, particularly focusing on advancements in artificial intelligence technologies and the proprietary HYFT analysis. Despite the positive outlook, the company emphasizes the inherent risks and uncertainties associated with future projections.
Read more →HYFTIPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024* VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reported strong financial results for the second quarter of FY24, with revenues reaching $6.2 million, marking an 18.6% increase from the same quarter last year. The company achieved its third consecutive record revenue quarter and reduced cash burn significantly. Continued growth was noted in both the B Cell Select platform and the manufacturing facility in Utrecht, which saw a notable 43% increase in revenue. Additionally, positive developments in BioStrand's offerings indicate a strong trajectory for revenue generation moving forward.
Read more →HYFTIPA Announces Closing of $1.265 Million Public Offering of Common Shares VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. has successfully closed a public offering, raising $1.265 million by selling 1,265,000 common shares at a price of $1.00 each. The proceeds from this offering will primarily fund research and development, capital expenditures, and general corporate purposes. The offering was managed by The Benchmark Company, which acted as the sole book-running manager. This move is part of the company's strategy to enhance its laboratory facilities and advance its biotherapeutic efforts.
Read more →HYFTIPA Announces Pricing of $1.1 Million Public Offering of Common Shares VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. announced the pricing of its public offering of 1,100,000 common shares at $1.00 per share, expected to yield approximately $1.1 million in gross proceeds. The offering is set to close on December 8, 2023, pending customary conditions. Proceeds will be used to fund research and development, capital expenditures, and general corporate purposes. Underwriters have also been given a 30-day option to purchase up to 165,000 additional shares, reflecting anticipated investor interest.
Read more →HYFTIPA Announces Proposed Public Offering of Common Shares VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. announced its intention to conduct an underwritten public offering of common shares. The proceeds are slated for research and development, as well as expansion of laboratory facilities. The company has granted underwriters a 30-day option for additional shares to cover any over-allotments. However, the offering's completion is contingent upon market conditions and there are no guarantees about the timing or specifics of the sale.
Read more →HYFTImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. has announced key changes in its Board of Directors, including Mitch Levine as the new Chairman. Levine's extensive experience in the life sciences sector is anticipated to enhance the company's strategies for growth and innovation, particularly in antibody development. Additionally, Chris Buyse and Dirk Witters have been appointed to lead the Remuneration and Nomination Committee and the Audit Committee, respectively. The company will host a conference call to discuss its second quarter fiscal 2024 earnings on December 14, 2023.
Read more →HYFTBioStrand Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research VICTORIA, British Columbia--(BUSINESS WIRE)
BioStrand has published a preprint detailing its innovative HYFT-based methodology for biological sequence retrieval. This approach uses patterns akin to biological fingerprints and shows clear advantages over the traditional BLAST algorithm. The publication aims to foster collaboration within the scientific community and emphasizes the scalable nature of HYFT technology amidst the increasing availability of sequencing data. ImmunoPrecise Antibodies Ltd., the parent company, sees this as a valuable advancement in AI-driven biotherapeutics.
Read more →HYFTFiled by newsfilecorp.com Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations In accordance with Section 11.3 of National Instrument 51-102 - Cont
ImmunoPrecise Antibodies Ltd. held its annual general meeting on November 9, 2023, via live webcast, where shareholders voted on key corporate matters. All five proposed nominees for the board of directors were elected, achieving over 93% approval. Additionally, Grant Thornton LLP was reappointed as the Corporation's auditors, also with strong backing. These results reflect robust shareholder confidence in the management team.
Read more →HYFTIPA's Subsidiary, BioStrand, Provides an Update on LENS ai BioStrand Unveils Groundbreaking Retrieval Augmented Generation (RAG)-Based LLM Platform Integrated with Patented HYFT Technology BioStrand's Work Exemplifies th
ImmunoPrecise Antibodies Ltd. has announced its subsidiary, BioStrand, has launched the LENSai platform, featuring a Retrieval Augmented Generation-based large language model combined with patented HYFT technology. This innovative platform aims to enhance drug discovery by integrating diverse data sources for better accuracy and analysis. Key features include the use of expansive knowledge graphs and a neuro-symbolic methodology to offer comprehensive insights into biological data. The rollout of the platform will involve a phased strategy to refine its capabilities based on user feedback.
Read more →HYFTIPA Provides Update on Growth Strategy and Recent Share Price Movement VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. (IPA) has announced updates to its growth strategy, focusing on the expansion of its contract research organization capabilities and leveraging advanced technology. The company recorded a 21.3% increase in revenue for the first quarter of fiscal 2024, alongside a notable 44.0% growth in its protein manufacturing facility. Despite a recent decline in share price, IPA remains optimistic about future growth, underlining its commitment to value creation. The company is also keen to enhance shareholder communication in the upcoming earnings call.
Read more →HYFTFiled by newsfilecorp.com IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 - 4464 Markham Street Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 9, 2023
ImmunoPrecise Antibodies Ltd. has announced its annual general meeting for shareholders, scheduled for November 9, 2023. The meeting will take place via live webcast, allowing shareholders to engage remotely. Key agenda items include the election of directors and the reappointment of auditors. Shareholders are encouraged to review the accompanying Information Circular for proxy voting details and to participate in the meeting.
Read more →HYFTFiled by newsfilecorp.com Form 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company IMMUNOPRECISE ANTIBODIES LTD. (the " Company ") 3204-4464 Markham Street, Victoria British Columbia, V8Z 7X8, Canada Item
ImmunoPrecise Antibodies Ltd. announced the resignation of Chief Financial Officer Brad McConn, effective September 29, 2023. Kristin Taylor, MBA, CPA, has been appointed as interim CFO. Taylor brings a strong background in executive management and investor relations, which aims to ensure a smooth transition in the company’s financial leadership. The change comes amidst a backdrop of potential risks associated with executive transitions that could impact operational performance.
Read more →HYFTImmunoPrecise Antibodies Announces CFO Transition Brad McConn to Step Down Later This Month Kristin Taylor, MBA, CPA, Named Interim CFO VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies has announced the resignation of Chief Financial Officer Brad McConn, effective September 29, 2023. Kristin Taylor has been named as the interim CFO, bringing a strong background in life sciences and capital markets to the role. The chairman of the board expressed gratitude for McConn's contributions and confidence in Taylor's ability to manage the transition seamlessly. ImmunoPrecise emphasizes its robust financial and accounting teams to ensure continuity during this change.
Read more →HYFTFiled by newsfilecorp.com IMMUNOPRECISE ANTIBODIES LTD. 3204 - 4464 Markham Street Victoria, British Columbia V8Z 7X8
ImmunoPrecise Antibodies Ltd. filed its Statement of Executive Compensation for the financial year ending April 30, 2023. The report details the compensation structure for named executive officers and outlines the company's approach to executive pay, emphasizing competitiveness within the industry. The compensation program includes base salary, short-term cash incentives, and stock options aimed at aligning executive interests with the company's long-term success. A benchmarking study was conducted to adjust compensation to ensure competitiveness in the market.
Read more →HYFTIPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 Company recorded record quarterly revenue, an increase of 21.3% compared to the same quarter last year. Significantly higher
ImmunoPrecise Antibodies Ltd. (IPA) reported its financial results for the first quarter of fiscal year 2024, highlighting a record revenue of $5.7 million, marking a 21.3% increase compared to the same quarter last year. The company also noted a significant rise in net income before taxes, increasing by approximately $6 million. In addition, IPA's manufacturing facility revenue saw a year-over-year growth of 44%. Although there were increases in general and administrative expenses and a decrease in cash reserves, the overall performance indicates a strong start to the year.
Read more →HYFTIPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on
ImmunoPrecise Antibodies Ltd. (IPA) announced it will host a conference call on September 14, 2023, to discuss its financial results and recent business highlights for the first quarter of fiscal year 2024. The call will be available via webcast and includes a question-and-answer session. As part of its commitment to transparency, the company will issue a press release with financial results prior to the call. IPA operates several subsidiaries in North America and Europe, focusing on biotherapeutic research and technology in antibody discovery.
Read more →HYFTIPA Announces Board Refreshment IPA appoints Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. (IPA) has appointed three new directors, Barry A. Springer, Dirk Witters, and Chris Buyse, to its Board of Directors, following a targeted search for optimal board composition. This move is intended to enhance the board's skills and experience, which are crucial for advancing the company's goals. Additionally, the company announced that Gregory S. Smith has resigned from his director position, and three incumbent non-executive directors will not seek re-election at the upcoming Annual General Meeting. These changes are aimed at maximizing shareholder value and improving governance.
Read more →HYFTIPA Responds to 13D Filing IPA responds to 13D Filing by Ingalls & Snyder, LLC VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. (IPA) has responded to a Schedule 13D filing by Ingalls & Snyder, LLC, expressing openness to shareholder communication. The company is currently interviewing candidates to refresh its board and has implemented a Majority Voting Policy to enhance corporate governance. This policy will require directors with more withheld votes than for votes to resign, reflecting IPA's commitment to shareholder support and accountability. IPA's proactive measures aim to align with its strategic priorities and maximize long-term shareholder value.
Read more →HYFTImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. has announced an exclusive interview event hosted by Market Radius Research, scheduled for July 19th. The webinar will feature Dr. Jennifer Bath, CEO of IPA, in discussions about the company's innovative AI-driven biotherapeutic research technology. Participants will have an opportunity to engage in a Q&A session post-interview. The event aims to provide valuable insights into ImmunoPrecise's advancements in biotherapeutic research and development.
Read more →HYFTImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023 The Company achieved revenue of $20.7 million during the year ended
ImmunoPrecise Antibodies Ltd. (IPA) released its financial results for the fiscal year 2023, reporting a revenue of $20.7 million, which represents a 6.7% year-over-year increase. The company also noted its highest quarterly revenue of $5.6 million for the last quarter. While the overall financial performance reflects growth, IPA faced a net loss that increased compared to the previous year, driven by rising research and development costs. Looking ahead, the company appears optimistic about leveraging their innovative services and collaborations to support continued growth.
Read more →HYFTIPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023. The Company to host an earnings conference call via webcast VICTORIA, British Columbia--(BUSIN
ImmunoPrecise Antibodies Ltd. (IPA) is set to report its financial results for the fourth quarter and fiscal year end 2023 on July 7th, 2023. The report will be followed by a conference call hosted by management, providing insights into recent business highlights. This event aims to strengthen communication with investors and stakeholders, emphasizing IPA's developments in biotherapeutic research and technology.
Read more →HYFTIPA's Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID) VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd., through its subsidiary BioStrand, has introduced a new use case for its Information Integration Dilemma solution. This use case highlights the integration of various data types via BioStrand's LENSai platform and HYFT technology, addressing longstanding challenges in biotechnology. The technology aims to foster enhanced biological discoveries by creating comprehensive data frameworks. Additionally, the success of this use case reflects ImmunoPrecise's ongoing commitment to innovation and leadership in AI-driven biotherapeutics.
Read more →HYFTIPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. (IPA) has launched a new AI-driven therapeutic screening platform powered by its HYFT technology, aiming to innovate the transgenic animal model market. This technology seeks to expedite drug discovery by optimizing early-stage candidate assessments, potentially reducing development costs and timelines significantly. The platform is designed to evaluate a wide range of therapeutic candidates simultaneously, overcoming limitations associated with traditional humanization processes. IPA targets major pharmaceutical clients to enhance operational efficiency and drive financial growth.
Read more →HYFTIPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. announced that its subsidiary BioStrand has solved the Information Integration Dilemma (IID) through a unique technology that integrates diverse biological data types. Utilizing its patented HYFT technology and the LENSai platform, BioStrand aims to enhance data fusion for improved biological analysis. This advancement is anticipated to expedite drug development and biomarker discovery while addressing longstanding challenges in the industry. The company's efforts demonstrate a commitment to innovation and improving patient outcomes.
Read more →HYFTIPA to Present at Jefferies Healthcare Conference 2023 VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced that its CEO, Dr. Jennifer Bath, will present at the Jefferies Healthcare Conference on June 9, 2023. This presentation aims to showcase the company's advancements in AI-driven biotherapeutic research and technology. The live and archived webcast will be accessible through the company's website, allowing stakeholders to gain insights into the company's initiatives.
Read more →HYFTFiled by newsfilecorp.com IMMUNOPRECISE ANTIBODIES LTD. STOCK OPTION PLAN 1. PURPOSE OF PLAN 1.1. Purpose . The purpose of the Stock Option Plan (the " Plan ") of IMMUNOPRECISE ANTIBODIES LTD., a company incorporated und
ImmunoPrecise Antibodies Ltd. has filed a Stock Option Plan aimed at motivating and retaining its directors, officers, employees, and consultants. The plan allows the specified individuals to acquire common shares, thereby increasing their stake in the company. This initiative is designed to align their interests with the growth and success of ImmunoPrecise, fostering stronger engagement in the company's operations.
Read more →HYFTImmunoPrecise's Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor Mi
ImmunoPrecise's subsidiary Talem has entered into an exclusive research collaboration and license option agreement with Astellas Pharma. The focus of this partnership is on using in silico and de novo discovery methods to develop antibodies against targets in the tumor microenvironment. The collaboration aims to enhance anti-tumor immunity by optimizing antibody candidates and leveraging Astellas' cell therapy technologies. This innovative approach is expected to pave the way for next-generation cancer therapies.
Read more →HYFTEuropean Patent Office to Grant BioKey's Patent Application for Foundational HYFT Technology Company Received Official Notice from the European Patent Office (EPO) for the Decision to Grant its Patent Application on Apri
The European Patent Office (EPO) has issued a decision to grant BioKey's patent application for its HYFT Technology, which efficiently organizes and analyzes biological sequence information. This technology plays a crucial role in regaining insights from omics data and will be integrated into BioStrand's LENSai Integrated Technology platform. With expectations of favorable outcomes in other countries, the patent strengthens BioStrand's market position and paves the way for advancements in drug discovery and patient outcomes. The announcement highlights the potential of HYFT Technology in cancer research and precision medicine.
Read more →HYFTImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates Company to Present at the Upcomi
ImmunoPrecise Antibodies Ltd. is set to present its innovative bispecific T-cell engaging antibodies at the upcoming AACR annual meeting. These antibodies target the Tropomyosin Receptor Kinase B (TrkB), which is linked to poor prognosis in multiple cancers. The company aims to demonstrate their potential to engage T cells in a more targeted manner, compared to existing therapies. ImmunoPrecise has filed a provisional patent application for their novel technology, highlighting its significance in cancer treatment development.
Read more →HYFTIPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 IPA's Project revenue increased by 16.7% compared to the prior year, driven by the growth of the company's proprietary B cel
ImmunoPrecise Antibodies Ltd. (IPA) reported a 16.7% increase in project revenue for Q3 FY 2023, driven by growth in its proprietary B cell platform. The company's gross profit also saw a rise of 14.6%, showcasing overall positive financial results. However, Talem Therapeutics, a subsidiary of IPA, encountered delays in the production of its COVID-19 therapeutic, PolyTope, necessitating adjustments to future milestones and a reduction in investment for this program. Despite these setbacks, IPA is pursuing new AI-based collaborations to enhance drug development efforts.
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE NINE MONTHS ENDED JANUARY 31, 2023 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited con
ImmunoPrecise Antibodies Ltd. provided its Management's Discussion and Analysis (MD&A) for the nine months ending January 31, 2023, where it reviewed its financial performance and strategic direction. The MD&A highlighted the company's advancements in biotherapeutic research including organic revenue growth and expansion into European markets. However, it also noted several risks and uncertainties associated with its business plans and R&D effectiveness. The document, approved by the company’s Board of Directors, emphasizes that actual results may significantly differ from forward-looking statements due to various risks.
Read more →HYFTFiled by newsfilecorp.com Form 51-102F3 MATERIAL CHANGE REPORT Item 1. - Name and Address of Corporation ImmunoPrecise Antibodies Ltd. (the Corporation or IPA ) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z
ImmunoPrecise Antibodies Ltd. (IPA) reported delays in the production of its anti-COVID therapeutic drug PolyTope, leading to a significant reduction in investment in this program. The company is working with its CDMO partner, ChemPartner, to resolve these issues while maintaining support from investors. Despite the setbacks, IPA has experienced positive revenue growth and is engaged in innovative collaborations, including one with Libera Bio to develop multi-target antibodies using AI technology.
Read more →HYFTImmunoPrecise Antibodies' Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio The program will leverage BioStrand's LENS ai Full Suite of Integrated Intellige
ImmunoPrecise Antibodies' subsidiary, Talem Therapeutics, has entered a collaboration with Libera Bio to develop an AI-driven antibody discovery program. This initiative will utilize Libera's Multifunctional Polymeric Nanocapsules to deliver antibodies to previously inaccessible intracellular targets associated with cancer. The agreement includes a minimum of USD 155 million in upfront and milestone payments, indicating a strong financial basis for the program. The partnership aims to address high unmet medical needs in oncology, representing a significant advancement in cancer therapy.
Read more →HYFTIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on
ImmunoPrecise Antibodies Ltd. (IPA) has announced an upcoming conference call to present its financial results and recent business highlights for the third quarter of fiscal year 2023. The call is scheduled for March 16, 2023, at 10:30 am ET, and will include a question-and-answer session facilitated by the company's management. Participants can join via dial-in or through a live webcast. The company operates several subsidiaries across North America and Europe, focusing on biotherapeutic research and technology innovation.
Read more →HYFTIPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs used as a navigational layer to parse over the p
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs used as a navigational layer to parse over the protein predictive platforms AlphaFold-2 and Evolutionary Sc
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE SIX MONTHS ENDED OCTOBER 31, 2022 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited cond
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE SIX MONTHS ENDED OCTOBER 31, 2022 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited condensed interim consolidated financial statements of Immuno
Read more →HYFTIPA's Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs and Accelerates in Silico Drug Discovery Developments Structural HYFT Technology is used as a navigational layer to parse over t
IPA's Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs and Accelerates in Silico Drug Discovery Developments Structural HYFT Technology is used as a navigational layer to parse over the protein predictive platforms AlphaFold-2 and Evolutionar
Read more →HYFTIPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022 The Company to host an earnings conference call via webcast VICTORIA, British Columbia--(BUSINESS WIRE)--December 5, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.)
Read more →HYFTIPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILA
IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA--(BUSINESS WIRE)--November 30, 2022--IPA (IMMUNOPRE
Read more →HYFTImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange VICTORIA, British Columbia--(BUSINESS WIRE)--November 22, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) announces that it has applied and has rece
Read more →HYFTFiled by newsfilecorp.com - 2 - IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 - 4464 Markham Street, Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual gene
IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 - 4464 Markham Street, Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general and special meeting (the "Meeting") of the shareholders of ImmunoPrecise Antibodies L
Read more →HYFTFiled by newsfilecorp.com
To: All Canadian Securities Regulatory Authorities Subject: IMMUNOPRECISE ANTIBODIES LTD. We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and Special Meeting Record Date for Notice of Me
Read more →HYFTIPA's Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs Under strategic collaboration, Talem, an IPA subsidiary, expands its relationship with Ligand/OmniAb, Inc., to develop three
IPA's Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs Under strategic collaboration, Talem, an IPA subsidiary, expands its relationship with Ligand/OmniAb, Inc., to develop three immuno-oncology programs targeting validated targets Talem
Read more →HYFTNIAID Confirms IPA's PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75 VICTORIA, British Columbia--(BUSINESS WIRE)
NIAID Confirms IPA's PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75 VICTORIA, British Columbia--(BUSINESS WIRE)--September 14, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), announc
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED JULY 31, 2022 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited conde
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED JULY 31, 2022 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoP
Read more →HYFTIPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 Structural HYFTs fully indexed and integrated in structure-function workflow LENSai data management platform successfully la
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 Structural HYFTs fully indexed and integrated in structure-function workflow LENSai data management platform successfully launches hyper-scalable solution for partner access, integra
Read more →HYFTIPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022 The Company to host an earnings conference call via webcast VICTORIA, British Columbia--(BUSINESS WIRE)--September 8, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.
Read more →HYFTLive Virus Assays at Ludwig-Maximilians-Universit t M nchen Confirm PolyTope's Efficacy Against SARS-CoV-2 Variants Including BA.5 VICTORIA, British Columbia--(BUSINESS WIRE)
Live Virus Assays at Ludwig-Maximilians-Universit t M nchen Confirm PolyTope's Efficacy Against SARS-CoV-2 Variants Including BA.5 VICTORIA, British Columbia--(BUSINESS WIRE)--August 29, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA)
Read more →HYFTImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022 The Company achieved record revenues of $19.4 million, up 8.1% from $17.9 million in fiscal year 2021 The Company achieved
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022 The Company achieved record revenues of $19.4 million, up 8.1% from $17.9 million in fiscal year 2021 The Company achieved record revenues of $5.2 million for the three months ended
Read more →HYFTIPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022 The Company to host an earnings conference call via webcast VICTORIA, British Columbia--(BUSINESS WIRE)--July 26, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD
Read more →HYFTHistopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA's PolyTope TATX-03, a Synergistic Antibody Cocktail against SARS CoV 2 Milest
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA's PolyTope TATX-03, a Synergistic Antibody Cocktail against SARS CoV 2 Milestone IPA Toxicity Study Supports the Safety of PolyTope TATX
Read more →HYFTIPA's Subsidiary BioStrand Secures Second VLAIO Research Grant IPA subsidiary BioStrand receives grant to expand LENSai platform by linking HYFTs with 3D protein structure and function DIEPENBEEK, Belgium--(BUSINESS WIRE
IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant IPA subsidiary BioStrand receives grant to expand LENSai platform by linking HYFTs with 3D protein structure and function DIEPENBEEK, Belgium--(BUSINESS WIRE)--May 9, 2022--Diepe IPA (IMMUNOPRECISE ANTIBODIES LTD.)
Read more →HYFTIPA's Advanced PolyTope TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern IPA's PolyTope TAT
IPA's Advanced PolyTope TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern IPA's PolyTope TATX-03 shows continuous validation of potent in vitro neutral
Read more →HYFTIPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings VICTORIA, British Columbia--
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings VICTORIA, British Columbia--(BUSINESS WIRE)--April 14, 2022--IPA (IMMUNOPRECISE ANTIBOD
Read more →HYFTFiled by newsfilecorp.com Form 51-102F3 MATERIAL CHANGE REPORT Item 1. - Name and Address of Reporting Issuer ImmunoPrecise Antibodies Ltd. (the Company or IPA ) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z
MATERIAL CHANGE REPORT Item 1. - Name and Address of Reporting Issuer ImmunoPrecise Antibodies Ltd. (the Company or IPA) 3204 - 4464 Markham Street, Victoria, British Columbia Item 2. - Date of Material Change Item 3. - News Release A news release with respect to the mater
Read more →HYFTFiled by newsfilecorp.com IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence New Platform I
IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence New Platform Integrates Sequence Data and Information from Entire Biosphere Acquisition includes
Read more →HYFTIPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence New Platform Integrates Sequence Data an
IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence New Platform Integrates Sequence Data and Information from Entire Biosphere Acquisition includes w
Read more →HYFTImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022 VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022 VICTORIA, British Columbia--(BUSINESS WIRE)--March 16, 2022--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-servic
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE NINE MONTHS ENDED JANUARY 31, 2022 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited con
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE NINE MONTHS ENDED JANUARY 31, 2022 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited condensed interim consolidated financial statements of Immun
Read more →HYFTIPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense Companies to pursue a low-volume injecta
IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense Companies to pursue a low-volume injectable formulation of IPA's COVID-19 antibody cocktail, PolyTo
Read more →HYFTIPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope TATX-03 In vivo, IND enabling evaluations of PolyTope TATX-03 in animal model show: There were no pharmacokinetic aberrations Injection with TAT
IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope TATX-03 In vivo, IND enabling evaluations of PolyTope TATX-03 in animal model show: There were no pharmacokinetic aberrations Injection with TATX-03 is well tolerated - with a significant safety margin
Read more →HYFTImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET VICTORIA, British Columbia--(BUSINESS WIRE)--March 8, 2022--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IP
Read more →HYFTImmunotherapeutic PolyTope from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant - Moves Towards FDA/IND-Submission During in vitro pseudovirus assays, IPA's PolyTope advanced immunotherapeutic TAT
Immunotherapeutic PolyTope from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant - Moves Towards FDA/IND-Submission During in vitro pseudovirus assays, IPA's PolyTope advanced immunotherapeutic TATX-03 prevents infection of cells by SARS-CoV-2 variant-of-c
Read more →HYFTImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability IPA Europe's Oss laboratories make a move to new Centre of Exc
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability IPA Europe's Oss laboratories make a move to new Centre of Excellence facilities in Oss, Netherlands, with progressive en
Read more →HYFTImmunoPrecise Antibodies Announces Grant of Stock Options VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies Announces Grant of Stock Options VICTORIA, British Columbia--(BUSINESS WIRE)--January 17, 2022--IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced
Read more →HYFTImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope TATX-03 Antibody Cocktail Manufacturing Collaboration VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope TATX-03 Antibody Cocktail Manufacturing Collaboration VICTORIA, British Columbia--(BUSINESS WIRE)--December 20, 2021--IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ: IPA) (TSX VENTURE: IPA) and
Read more →HYFTImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022 VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022 VICTORIA, British Columbia--(BUSINESS WIRE)--December 13, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-se
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE SIX MONTHS ENDED OCTOBER 31, 2021 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited cond
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE SIX MONTHS ENDED OCTOBER 31, 2021 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited condensed interim consolidated financial statements of Immuno
Read more →HYFTImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022 The Company to host an earnings conference call via webcast on
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022 The Company to host an earnings conference call via webcast on December 13, 2021 at the close of market VICTORIA, British Columbia--(BUSINESS WIRE)--December 7, 2021--IMMU
Read more →HYFTImmunoPrecise Update on its SARS-CoV-2 PolyTope Multi-Antibody Cocktail Development Program Polytope Reaches Multiple Milestones and IPA Has Commenced Omicron Variant Analysis VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Update on its SARS-CoV-2 PolyTope Multi-Antibody Cocktail Development Program Polytope Reaches Multiple Milestones and IPA Has Commenced Omicron Variant Analysis VICTORIA, British Columbia--(BUSINESS WIRE)--November 30, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Co
Read more →HYFTImmunoPrecise to Present at the Benchmark Company's Discovery One-on-One Virtual Video Investor Conference on Thursday
ImmunoPrecise to Present at the Benchmark Company's Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021 VICTORIA, British Columbia--(BUSINESS WIRE)--November 24, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTU
Read more →HYFTIPA Announces Resignation of Director VICTORIA, British Columbia--(BUSINESS WIRE)
IPA Announces Resignation of Director VICTORIA, British Columbia--(BUSINESS WIRE)--November 9, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) announced today that Paul Andreola, a member of the Board of Directors of IPA, has resigne
Read more →HYFTNOTICE OF CHANGE OF AUDITOR TO: Grant Thornton LLP Crowe MacKay LLP AND TO: British Columbia Securities Commission Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan The Manitoba Secur
NOTICE OF CHANGE OF AUDITOR TO: Grant Thornton LLP Crowe MacKay LLP AND TO: British Columbia Securities Commission Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan The Manitoba Securities Commission Ontario Securities Commission
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. Unit 3204 4464 Markham Street Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 30, 2021
IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 4464 Markham Street Victoria, BC V8Z 7X8 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 30, 2021 This document requires immediate attention. If you are in doubt as to how to deal with the documents or matters referred t
Read more →HYFTImmunoPrecise Announces At-The-Market Facility of up to US$50 Million VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million VICTORIA, British Columbia--(BUSINESS WIRE)--October 13, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery a
Read more →HYFTTalem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre Multi-target research collaboration leverages ImmunoPrecise's powerful antibody discovery technologies with the long-s
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre Multi-target research collaboration leverages ImmunoPrecise's powerful antibody discovery technologies with the long-standing expertise of Pierre Fabre in VICTORIA, British Col
Read more →HYFTImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 VICTORIA, British Columbia--(BUSINESS WIRE)--September 9, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-ser
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED JULY 31, 2021 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited conde
IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED JULY 31, 2021 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoP
Read more →HYFTImmunoPrecise's Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise's Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation VICTORIA, British Columbia--(BUSINESS WIRE)--September 8, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic
Read more →HYFTImmunoPrecise Announces Participation at the H.C. Wainwright 23 nd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference) VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Announces Participation at the H.C. Wainwright 23 nd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference) VICTORIA, British Columbia--(BUSINESS WIRE)--September 7, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IP
Read more →HYFTImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 The Company to host an earnings conference call via webcast on
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022 The Company to host an earnings conference call via webcast on September 9, 2021, at the close of market VICTORIA, British Columbia--(BUSINESS WIRE)--September 3, 2021--IMM
Read more →HYFTImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans Dr. Barry Duplantis, Ph.D., promoted to VP of Client Relations
ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans Dr. Barry Duplantis, Ph.D., promoted to VP of Client Relations Carla Dahl, appointed to VP of Marketing VICTORIA, Britis
Read more →HYFTImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021 Total revenue of $17.9 million, up 27% from $14.1 million in fiscal 2020 Successfully dual listed to Nasdaq Global Market,
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021 Total revenue of $17.9 million, up 27% from $14.1 million in fiscal 2020 Successfully dual listed to Nasdaq Global Market, subsequently raised USD$25 million in bought deal offering
Read more →HYFTImmunoPrecise's PolyTope TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays IPA publishes its scientific paper "Cornering an Ever-Evolving Coronavirus: TATX-03, a Fully
ImmunoPrecise's PolyTope TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays IPA publishes its scientific paper "Cornering an Ever-Evolving Coronavirus: TATX-03, a Fully Human, Synergistic, Multi-Antibody Cocktail Targeting the
Read more →HYFTImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021 The Company to host an earnings conference call via webcast on
ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021 The Company to host an earnings conference call via webcast on July 28, 2021, after the close of market VICTORIA, British Columbia--(BUSINESS WIRE)--July 15, 2021--IMMUNOPRECISE ANTIBODIES LT
Read more →HYFTEurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform VICTORIA, British Columbia--(BUSINESS WIRE)
Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform VICTORIA, British Columbia--(BUSINESS WIRE)--June 22, 2021--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-se
Read more →HYFTHistopathology Preclinical Data from ImmunoPrecise's Polytope Program Confirms Lung Inflammation Reduction Treatment with TATX-03a substantially reduced bronchitis and tracheitis severity in preclinical studies - New his
Histopathology Preclinical Data from ImmunoPrecise's Polytope Program Confirms Lung Inflammation Reduction Treatment with TATX-03a substantially reduced bronchitis and tracheitis severity in preclinical studies - New histopathology data show that the significantly reduced viral
Read more →HYFTPreclinical Data from ImmunoPrecise's Drug Pipeline to be Presented During the BIO International Partnering Event VICTORIA, British Columbia--(BUSINESS WIRE)
Preclinical Data from ImmunoPrecise's Drug Pipeline to be Presented During the BIO International Partnering Event VICTORIA, British Columbia--(BUSINESS WIRE)--June 15, 2021--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced th
Read more →HYFTImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche VICTORIA, British Columbia--(BUSINESS WIRE)--June 2, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IP
Read more →HYFTImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board VICTORIA, British Columbia--(BUSINESS WIRE)--May 25, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and developm
Read more →HYFTImmunoPrecise Moves SARS-CoV-2 PolyTope Cocktail Program's Path Toward IND Filing - Demonstrating what the Company believes to be the first reported in vivo synergistic effects of a multi-antibody (3+) combination treatm
ImmunoPrecise Moves SARS-CoV-2 PolyTope Cocktail Program's Path Toward IND Filing - Demonstrating what the Company believes to be the first reported in vivo synergistic effects of a multi-antibody (3+) combination treatment - Dr. Ilse Roodink and Dr. Debby Kruijsen to host live
Read more →HYFTImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record VICTORIA, British Columbia--(BUSINESS WIRE)--April 21, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discov
Read more →HYFTImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease Potential to Treat Parkinson's and Other Neurodegenerative Diseases VICTORIA, British Columbia--(BUSINESS WI
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease Potential to Treat Parkinson's and Other Neurodegenerative Diseases VICTORIA, British Columbia--(BUSINESS WIRE)--April 8, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Co
Read more →HYFTImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern Blocks the RBD/ACE2 binding interaction indire
ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action Binds to a
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE NINE MONTHS ENDED JANUARY 31,2021 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited cond
Exhibit 99.1 IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE NINE MONTHS ENDED JANUARY 31,2021 The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited condensed interim consolidated financial state
Read more →HYFTImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease ImmunoPrecise and Lit
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease ImmunoPrecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-
Read more →HYFTImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of
ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy VICT
Read more →HYFTImmunoPrecise Announces Participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021 (Virtual Conference) Management to provide corporate update on emerging SARS-CoV-2 variants of concern, (UK
ImmunoPrecise Announces Participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021 (Virtual Conference) Management to provide corporate update on emerging SARS-CoV-2 variants of concern, (UK, S. African and Brazilian) VICTORIA, British Columbia--(B
Read more →HYFTImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope Monoclonal Antibody Cocktail Candidate Against COVID-19 Treatment of Syrian hamsters with TATX-03, a cocktail of four proprietary monoclonal antibod
ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope Monoclonal Antibody Cocktail Candidate Against COVID-19 Treatment of Syrian hamsters with TATX-03, a cocktail of four proprietary monoclonal antibodies directed against distinct regions of the SARS-CoV-2 spi
Read more →HYFTIPA Announces Closing of Over-Allotment Option Associated with the Recently Completed Bought Deal Offering of Common Shares VICTORIA, British Columbia
IPA Announces Closing of Over-Allotment Option Associated with the Recently Completed Bought Deal Offering of Common VICTORIA, British Columbia, February 10, 2021 IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA ) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, ther
Read more →HYFTIPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares VICTORIA, British Columbia
IPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares VICTORIA, British Columbia, February 8, 2021 IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA ) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and developmen
Read more →HYFTIMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2020 AND 2019 (Unaudited Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDE
IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2020 AND 2019 (Unaudited Expressed in Canadian Dollars) IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSIT
Read more →HYFTImmunoPrecise Antibodies to Participate in January Conferences VICTORIA, British Columbia--(BUSINESS WIRE)
ImmunoPrecise Antibodies to Participate in January Conferences VICTORIA, British Columbia--(BUSINESS WIRE)--January 6, 2021--IMMUNOPRECISE ANTIBODIES LTD. ("IPA") (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today announced that Dr. Jennife
Read more →HYFTImmunoPrecise Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Program Innovative, novel approach to treat and protect against SARS-CoV-2 using thermoresponsive virus-targeting nanoparticles as an inhalation medicin
ImmunoPrecise Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Program Innovative, novel approach to treat and protect against SARS-CoV-2 using thermoresponsive virus-targeting nanoparticles as an inhalation medicine Program includes development of a heat-sensitive fluores
Read more →Competitive Position
How HYFT ranks across every disease it competes inCompetitive Position is a premium feature
See how HYFT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial